We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World’s First Molecular, Cell-Based Test Offers Non-Surgical Method for Diagnosis and Staging of Endometriosis

By LabMedica International staff writers
Posted on 25 Jan 2023

Endometriosis is a very painful disorder in which tissue similar to that which normally lines the uterus migrates and grows on other organs outside of the uterus. More...

The disease affects about 10-20% of women across the world and is responsible for a high majority of female infertility cases. Awareness of a patient’s endometriosis status and stage can save significant amounts of money spent on misdiagnosis and interventions that could be unsuitable for the stage of the disease. Additionally, during infertility, treatment of the underlying endometriosis before intervention can increase the chances of success by modifying the interventions after taking into account the underlying disease. Now, researchers will soon begin a clinical trial evaluating the world’s first molecular, cell-based test for diagnosing and staging endometriosis without surgery.

Hera Biotech (San Antonio, TX, USA) is developing and commercializing the world’s first non-surgical test for the definitive diagnosis and staging of endometriosis. Hera’s breakthrough approach is based on cutting edge, single cell, micro-fluidic analysis to identify endometriosis-specific biological markers. This approach enables clinicians to definitively diagnose endometriosis regardless of stage with unparalleled accuracy. A sample of the patient’s endometrium is collected using a uterine brush biopsy during an in-office procedure, thereby eliminating the need for surgery. MetriDx configuration utilizes micro-fluidic analysis of single cells obtained from the patient to definitively diagnose and stage endometriosis.

MetriDx can provide physicians with unprecedented diagnostic capability, reduce the liability risk for hospitals, eliminate unnecessary surgical procedures, and minimize the amount of time for patients before they receive a diagnosis, all the while maintaining tissue collection and a direct pathology diagnosis. MetriDx will initially be offered to both OB/GYN practices and those in the fertility solutions market as a laboratory developed test (LDT). MetriDx can also be utilized as a screening test in OB/GYN practices, in fertility clinics and by reproductive endocrinologist practices. The first patient for the proof-of-concept multi-center clinical trial of the MetriDx endometriosis diagnostic test has already been enrolled.

“Women in the US endure eight years and ten plus doctor’s visits, on average, before they get a diagnosis,” said CEO and Co-Founder Somer Baburek. “I want the process for obtaining a definitive answer about your endometriosis status to be as easy and as routine as getting a pap smear.”

Related Links:
Hera Biotech 


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.